Table S1: Baseline characteristic of patients with ALT>/=1000 IU/L.

	Frequency	Percent
Drugs for acid related disorders	28	6.9
Drugs for functional gastrointestinal disorders	5	1.2
Antiemetics and antinauseants	2	0.5
Drugs for constipation	2	0.5
Antidiarrheals, intestinal anti-inflammatory agents	1	0.2
Antidiabetics	23	5.7
Vitamins	11	2.7
Mineral supplements	4	1
Other alimentary tract and metabolism products	3	0.7
Antithrombotic agents	30	7.4
Cardiac therapy	1	0.2
Antihypertensives	21	5.2
Diuretics	8	2
Beta blocking agents	16	4
Calcium channel clockers	7	1.7
Agents acting on the renin-angiotensin-system	19	4.7
Lipid modifying agents	19	4.7
Antipruritic	1	0.2
Corticosteroids, dermatological preparations	2	0.5
Other dermatological preparations	1	0.2
Sex hormones and modulators of gynecological system	1	0.2
Urologicals	12	3
Pituitary and hypothalamic hormones	3	0.7
Corticosteroids for systemic use	3	0.7
Thyroid therapy	9	2.2
Antibacterial	7	1.7
Antivirals	4	1
Antineoplastic agents	1	0.2
Anti-inflammatory and antirheumatic products	47	11.6
Muscle relaxants	2	0.5
Antigout preparations	4	1
Analgesics	15	3.7
Antiepileptics	10	2.5
Psycholeptics	12	3
Psychoanaleptics	19	4.7
Nasal preparations	5	1.2

Correspondence to: Redona Hafizi, Department of Partner Relations and Medical Affairs, TOM Medication, Wermatswil, Switzerland, E-mail: redona.hafizi@tommedications.com

Table S2: Distribution of DDI relevance classes using Medscape drug-drug interaction.

	Frequency	Percent
Class 1	3	6.7
Class 2	5	11.1
Class 3	19	42.2
Class 4	2	4.4
Class 5	1	2.2
Total	30	66.7
Missing system	15	33.3
Total	45	100

Table S3: Distribution of DDIs using Epocrates online.

	Frequency	Percent
Class 1	1	2.2
Class 2	7	15.6
Class 3	22	48.9
Total	30	66.7
Missing system	15	33.3
Total	45	100

Table S4: Frequency of the medications involved in DDIs.

	Frequency	Percent
Diazepam	1	1.1
Clarithromycin	2	2.3
Pantoprazol	1	1.1
Escitalopram	1	1.1
Allopurinol	1	1.1
Bisoprolol	3	3.4
Perindopril-amlodipine-indapamide	1	1.1
Torsemide	2	2.3
Quetiapine	1	1.1
Candesartan	1	1.1
Mephenamic acid	2	2.3
Paracetamol	1	1.1
Aspirin	1	1.1
Ibuprofen	3	3.4
Diclofenac sodium	1	1.1
Levothyroxine	1	1.1
Rivaroxaban	1	1.1
Ramipril	3	3.4
Rosuvastatin	1	1.1
Insulin deglutec	1	1.1
Metformin	3	3.4
Irbesartan-hydrochlorothiazide	3	3.4
Naproxen	1	1.1
Clopidogrel	2	2.3
Sacubitril-valsartan	2	2.3
Mirtazapine	4	4.5
Amlodipine	2	2.3

Dimentindene	1	1.1
Amlodipine-valsartan-hydrochlorothiazide	3	3.4
Lisdexamphetamine dimesylate	1	1.1
Bupropion hydrochloride	3	3.4
Valsartan	1	1.1
Metolazone	2	2.3
Perindopril-amlodipine	1	1.1
Simvastatin	1	1.1
Lorazepam	1	1.1
Estradiol-dydrogesterone	1	1.1
Acemetacin	1	1.1
Sitagliptin	1	1.1
Ramipril-hydrochlorothiazide	2	2.3
Moxonidine	1	1.1
Metoprolol	2	2.3
Phenytoin	1	1.1
Telmisartan	1	1.1
Candesartan-hydrochlorothiaze	1	1.1
Venlafaxine	1	1.1
Nifedipine	1	1.1
Digoxin	1	1.1
Captopril	1	1.1
Bisoprolol-hydrochlorothiazide	1	1.1
Naproxen-esomeprazole	1	1.1
Methylphenidate	4	4.5
Trazodone	4	4.5
Phentanyl	1	1.1
Duloxetine	1	1.1
Paracetamol-dextrometorphan-Pseudoephedrine-doxylamine	1	1.1
Total	88	100

Table S5: Drug-Drug Combinations mainly involved in moderate and major DDIs and their mechanism of action.

Drug-Drug Interaction		Severity	Mechanism of Action	Frequency (%)
Drug 1	Drug 2			
Allopurinol	Perindopril	Moderate	UNK	1
Bisoprolol	Insulin deglutec	Moderate	PD	1
Irbesartan-hydrochlorothiazide	Naproxen	Moderate	PD	1
Dimentindene	Mirtazapine	Moderate	UNK	1
Mephenamic acid	Clopidogrel	Moderate	PD	1
Rivaroxaban	Ibuprofen	Moderate	PD	1
Telmisartan	Ibuprofen	Moderate	PD	1
Clopidogrel	Rosuvastatin	Moderate	PK	1
Quetiapine	Venlafaxine	Moderate	UNK	1
Bisoprolol	Nifedipine	Moderate	PD	1

Amlodipine-valsartan-hydrochlorothiazide	Digoxin	Moderate	PD+PK	1
Paracetamol-dextrometorphan-pseudoephedrine-doxylamine	Captopril	Moderate	PD	1
Ramipril	Spironolactone	Moderate	PD	1
Amlodipine-valsartan-hydrochlorothiazide	Ramipril	Moderate	PD	1
Bupropion hydrochloride	Methylphenidate	Moderate	PD	1
Bupropion hydrochloride	Trazodone	Moderate	UNK	1
Bisoprolol-hydrochlorothiazide	Naproxen	Moderate	PD+PK	1
Amlodipine-valsartan-hydrochlorothiazide	Mephenamic acid	Moderate	PD	1
Lorazepam	Fentanyl	Moderate	PD	1
Valsartan	Metolazone	Moderate	UNK	1
Metoprolol	Amlodipine	Moderate	UNK	1
Metformin	Metolazone	Moderate	PD	1
Duloxetine	Mirtazapine	Moderate	UNK	1
Diclofenac sodium	Aspirin	Moderate	PD	1
Candesartan-hydrochlorothiazide	Ibuprofen	Moderate	PD	1
Bupropion- hydrochloride	Lisdexamphetamine	Major	UNK	1
Trazodone	Methylphenidate	Major	PD	2
Methylphenidate	Trazodone	Major	PD	1
Clarithromycin	Diazepam	Contraindicated	PK	1
Clarithromycin	Escitalopram	Contraindicated	PD	1
Sacubitril-valsartan	Ramipril	Contraindicated	PD	1
Diclofenac sodium	Aspirin	Moderate	PD	1

Table S6: Distribution of duplicate therapies based on the intention of the duplicate therapy.

	Frequency	Percent
Unwanted	11	33.3
Potentially unwanted	15	45.5
Wanted	7	21.2
Total	33	100

Table S7: Cross tabulation of Duplicate Therapy and DDI variables.

Is a DDI present?		Is a duplicate therapy present		
		Yes	No	Total
Yes	Count	18	16	34
	Expected count	11.2	22.8	34
No	Count	15	51	66
	Expected count	21.8	44.2	66
Total	Count	33	67	100
	Expected count	33.0	67	34

Table S8: Logistic regression model of predictors of duplicate therapy.

Covariate	OR (Exp(B))	95% Confidence Interval	P-value
The total number of medication	1.795	(1.178, 2.737)	0.07
Is there a DDI present?	2.261	(0.850, 6.016)	0.102